NET ASSET VALUE – 31 January 2025
On the 31 January 2025 Flerie AB's Net Asset Value (NAV) was SEK 4,211 million and NAV per share was SEK 53.94.
| Allocation of NAV | Share of portfolio company | Fair value (MSEK) | Part of NAV per share (SEK) | Share of NAV |
| Product Development | ||||
| Prokarium | 42% | 482 | 6.18 | 11.5% |
| Xspray Pharma | 18% | 225 | 2.89 | 5.4% |
| KAHR Medical | 31% | 208 | 2.67 | 5.0% |
| Empros Pharma | 79% | 204 | 2.62 | 4.9% |
| Atrogi | 37% | 176 | 2.25 | 4.2% |
| Lipum | 57% | 166 | 2.13 | 3.9% |
| Xintela | 61% | 163 | 2.09 | 3.9% |
| Microbiotica | 10% | 137 | 1.76 | 3.3% |
| Geneos Therapeutics | 12% | 106 | 1.36 | 2.5% |
| Toleranzia | 66% | 105 | 1.35 | 2.5% |
| Mendus | 24% | 86 | 1.10 | 2.0% |
| AnaCardio | 17% | 69 | 0.89 | 1.6% |
| EpiEndo Pharmaceuticals | 9% | 57 | 0.73 | 1.4% |
| Vitara Biomedical | 10% | 55 | 0.71 | 1.3% |
| Synerkine Pharma | 43% | 53 | 0.68 | 1.3% |
| Egetis Therapeutics | 2% | 36 | 0.46 | 0.9% |
| Buzzard Pharmaceuticals | 14% | 29 | 0.37 | 0.7% |
| Sixera Pharma | 24% | 27 | 0.35 | 0.6% |
| Alder Therapeutics | 21% | 17 | 0.22 | 0.4% |
| Amarna Therapeutics | 58% | 12 | 0.15 | 0.3% |
| Strike Pharma | 16% | 9 | 0.11 | 0.2% |
| Total | 2,423 | 31.04 | 57.5% | |
| Commercial Growth | ||||
| NorthX Biologics | 92% | 189 | 2.42 | 4.5% |
| Symcel | 31% | 174 | 2.23 | 4.1% |
| Nanologica | 43% | 82 | 1.05 | 1.9% |
| Provell Pharmaceuticals* | 72% | 81 | 1.04 | 1.9% |
| Chromafora | 31% | 73 | 0.93 | 1.7% |
| A3P Biomedical | 8% | 46 | 0.59 | 1.1% |
| Frontier Biosolutions | 2% | 19 | 0.24 | 0.5% |
| Bohus Biotech | 45% | 17 | 0.21 | 0.4% |
| Total | 680 | 8.71 | 16.2% | |
| Limited Partnerships, total | 97 | 1,24 | 2,3% | |
| Assets related to Portfolio companies | 217 | 2.77 | 5.1% | |
| Other assets and liabilities | 794 | 10.17 | 18.9% | |
| Net asset value | 4,211 | 53.94 | 100.0% | |
* indirect shares in Provell Pharmaceuticals